Novel Psychoactive Substances and legislative harmonization in Europe: addressing a extremely elusive public health threat

Main Article Content

Federica Umani Ronchi


Novel Psychoactive Substances (NPS), Drug enforcement, EU legislative frameworks


Download data is not yet available.
Abstract 75 | PDF Downloads 47


1.Mannocchi G, Di Trana A, Tini A, et al. Development and validation of fast UHPLC-MS/MS screening method for 87 NPS and 32 other drugs of abuse in hair and nails: application to real cases. Anal Bioanal Chem. 2020 Aug;412(21):5125-5145.
2.Marchei E, Tini A, Pirani F, Lo Faro AF, Marinelli S. Is GHB-glucuronide useful as a biomarker for the exogenous use of GHB? Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2311-2313. 
3.Marinelli S, Berretta P, Pacifici R, Del Rio A. Sex enhancers: challenges, threats and the need for targeted measures. Clin Ter. 2019 May-Jun;170(3):e181-e183.
4.Negro F, Di Trana A, Marinelli S. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs. Acta Biomed. 2022 Jan 19;92(6):e2021401.
5.The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Legal approaches to controlling new psychoactive substances. Updated on 31st May 2016. Available online: (Accessed on 19th January 2023).
6.The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System December 2020. Available online: (Accessed on 19th January 2023).